Diabetes and cardiometabolic companies compete on evidence, payer agreements, and clinical positioning – not features alone. We create a competitive intelligence function that monitors what truly influences deals in this category, so you are never the last to find out.
The Problem
The competition that counts is clinical evidence and payer wins, not lists of features
In diabetes and cardiometabolic health, deals turn on published outcomes, clinical validity, and which payers and employers a competitor has signed – not the feature comparison most competitive tracking obsesses over. A CI effort that logs competitors' UI changes while missing a new outcomes study or a big payer win is watching the wrong game. Tracking the evidence and contract moves that actually decide deals is a category-specific skill generic CI does not have.
You discover competitor moves through deals you have already lost
Without a deliberate intelligence function, you discover a competitor's new evidence, pricing, or payer partnership when a buyer cites it in a deal you are losing. By then the narrative is set and you are reacting from behind. Finding out about the moves that shape your market from the market itself, deal by deal, is the most expensive way to stay informed.
Sales enters deals unprepared to answer the competitor's story
When a payer or employer is also evaluating a competitor, your sales team needs a clear, honest account of how you differ on the dimensions that matter – evidence, cost impact, integration – and most teams improvise it. Improvised competitive responses come across as defensive or inaccurate and lose winnable deals. Equipping sales with real, current competitive positioning is where intelligence turns into revenue.
Raw competitor information accumulates without ever informing a decision
Some teams collect competitor information but never turn it into anything – a folder of screenshots and press releases that nobody uses to change positioning, pricing, or roadmap. Intelligence that does not reach a decision is just noise that consumes effort. The gap between gathering competitor data and acting on it is where most CI efforts quietly fail.
How We Support You
We begin by determining which intelligence genuinely matters to your deals – which competitors, and which of their actions (outcomes studies, payer and employer wins, pricing changes, clinical positioning) would alter how you sell or what you build. For this category, that means following evidence and contracts rather than feature logs, and it ties into our wider [growth strategy](/services/strategy/) work so intelligence drives actual decisions.
Strategy creates the tracking system: the sources, cadence, and framework used to monitor the competitive dimensions that determine diabetes and cardiometabolic deals. We concentrate on signals that influence buyers – a new outcomes publication, a health plan signing, a repositioning – instead of getting buried in low-value noise.
Execution transforms raw signals into practical positioning and enablement through our [marketing](/services/marketing/) practice: accurate, up-to-date battlecards and competitive narratives that help sales address a competitor's story in the room without sounding defensive or misleading. We ground everything in fact – misrepresenting a competitor creates both legal and credibility risks – so the positioning withstands buyer scrutiny.
We also establish the loop that converts intelligence into decisions: a cadence that puts competitive moves in front of those responsible for positioning, pricing, and roadmap, connected to our [measurement](/services/measurement/) layer so you can identify how competitive dynamics affect win rates. This prevents intelligence from accumulating unused.
Measurement evaluates whether the function improves outcomes – win rate against named competitors, fewer deal surprises, quicker responses to market moves – not the volume of competitor updates recorded. Intelligence is assessed by decisions and deals, not quantity.
We do not create a folder filled with competitor screenshots – we develop an intelligence function aligned with how diabetes and cardiometabolic deals are actually won or lost.
What we deliver
- A map of the competitors and competitive moves that actually affect your deals
- A tracking system focused on evidence, payer wins, and positioning shifts
- Honest, current battlecards and competitive narratives for sales
- An intelligence loop that reaches positioning, pricing, and roadmap decisions
- Early warning on competitor evidence and contract moves
- Measurement tied to win rate and fewer deal surprises, not data volume
In diabetes and cardiometabolic health, clinical evidence and payer contracts determine deals—so competitive intelligence focused on feature updates is following the wrong game, and the function only proves its value when it alerts you to a competitor's new outcomes study or payer win before your buyer does.
Our Methodology
Our 90-day sprint establishes a competitive intelligence function designed for this category. Days 1-30 focus on assessment: we determine which competitors truly influence your deals, define the actions worth monitoring (outcomes studies, payer and employer wins, pricing, positioning), audit where surprises currently occur, and inventory the intelligence you already possess but do not use. The phase concludes with a competitor map and tracking framework.
Days 31-60 cover building and enablement. We implement the tracking system and cadence, then translate signals into accurate, current battlecards and competitive narratives that prepare sales to respond to competitor stories in the room. Each competitive claim is fact-based and verified because misrepresenting a competitor poses credibility and legal risks that cost more than they deliver.
Days 61-90 address the decision loop and measurement. We establish the cadence that brings competitive moves to the people responsible for positioning, pricing, and roadmap, link competitive dynamics with win-rate data, and document the function so your team can operate it. Since the value of intelligence depends on continued vigilance, the sprint creates a sustainable function instead of a one-off competitor report.
Our Working Approach
During the first 30 days, we collaborate with your sales, product, and founder stakeholders because they understand where deals are lost and which competitor actions would alter decisions. Expect working sessions that identify the relevant competitors, define signals worth monitoring, and uncover where you repeatedly get surprised.
Days 30-60 shift to system building and sales enablement. Instead of delivering a data dump, we establish focused tracking and convert signals into accurate, current battlecards and narratives your team can apply in live deals. Every competitive claim remains factual and defensible because an inaccurate battlecard destroys buyer credibility faster than saying nothing.
Days 60-90 center on measurement and the decision loop. We set up the cadence that puts intelligence before decision-makers, connect competitive dynamics with win rate, and transfer the function to your team. Because intelligence creates competitive advantage by remaining current, most engagements last 4-6 months to establish a sustainable function rather than capture a snapshot.
The team includes a strategist who leads the intelligence framework and decision loop, a content specialist who creates sales-ready narratives and battlecards, and a measurement resource who connects competitive dynamics to win rate – scaled according to competitor count and deal complexity, rather than offered as a fixed package.
- Early warning on competitor evidence and payer moves instead of learning in-deal
- Sales equipped to answer competitor stories accurately and confidently
- Intelligence that reaches positioning, pricing, and roadmap decisions
- Focus on the evidence and contract signals that actually decide deals
- Improved win rate against specific competitors, tracked directly
If your diabetes & cardiometabolic health company needs competitive intelligence leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does a competitive intelligence engagement cost for a diabetes or cardiometabolic company?
Engagements generally cost $10K-$25K/month, based on the number of competitors monitored, the cadence, and the extent of sales enablement we create. Pricing reflects the tracking system's depth and the volume of battlecards and narratives – not a set report count. Since losing a payer or employer deal because of a competitor surprise is costly, the investment is evaluated against the value of deals that stronger intelligence helps you win.
What should competitive intelligence monitor in this category?
The signals that determine deals – published outcomes studies, clinical validity, payer and employer wins, pricing changes, and positioning shifts – not the UI and feature logs that occupy generic CI. Evidence and contracts influence buyers in diabetes and cardiometabolic health, so that is what we track. A CI program monitoring feature lists while overlooking a new outcomes study is following the wrong game.
How do you ensure our competitive claims remain accurate and defensible?
We verify and ground every battlecard and competitive narrative in fact because misrepresenting a competitor creates both a legal risk and a credibility risk with skeptical buyers. Accurate, current positioning that recognizes a competitor's genuine strengths performs better than defensive spin. We never invent competitor weaknesses or exaggerate your advantages – accuracy makes the enablement practical in a real room.
How do you ensure the intelligence is actually put to use?
We establish a decision loop – a cadence that brings competitive moves to the people responsible for positioning, pricing, and roadmap – so intelligence influences decisions rather than collecting in a folder. Competitor data that never informs a decision is simply noise, making that gap a central focus of the function. Leadership briefings and sales enablement are the mechanisms that transform signals into action.
How do you determine whether competitive intelligence is effective?
We measure win rate against named competitors, how often deal surprises occur, and the speed of your response to market moves – outcomes rather than the number of competitor updates recorded. Intelligence volume is an input; its value appears in decisions and deals. When win rate against a specific competitor rises and buyers no longer catch you off guard, the function is succeeding.
What does it look like to get started with competitive intelligence?
We start by identifying the competitors that truly influence your deals, defining which moves deserve monitoring, and uncovering where you repeatedly get surprised. This produces a focused competitor map and tracking framework before the complete function is built. If your diabetes or cardiometabolic company continues discovering competitor moves through lost deals, we should talk.
